Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and.

Slides:

Advertisements

Similar presentations

Neutron radiation therapy for advanced thyroid cancers Tobias R. Chapman, MD, George E. Laramore, PhD, MD, Stephen R. Bowen, PhD, Peter F. Orio, DO, MS.

Advertisements

Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial K. Ranh Voong, MD MPH, Lincy S. Lal, PhD, Deborah.

Detection of recurrent prostate cancer after primary radiation therapy: An evaluation of the role of multiparametric 3T magnetic resonance imaging with.

Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes Stuart E. Samuels, MD, PhD, Matthew.

Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer Victor E. Chen, BS, Erin.

John Boyle, MD, Brad Ackerson, MD, Lin Gu, MS, Chris R. Kelsey, MD

Death from thyroid cancer of follicular cell origin1

Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports Daniel K. Ebner, BS, Tadashi Kamada, MD, PhD,

Incorporating big data into treatment plan evaluation: Development of statistical DVH metrics and visualization dashboards Charles S. Mayo, PhD, John.

Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity Sarah J. Stephens, MD, Samantha Thomas, MB,

Jerry D Slater, M. D. , Carl J Rossi, M. D. , Les T Yonemoto, M. D

Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate.

Sociodemographic disparities in the utilization of proton therapy for prostate cancer at an urban academic center Kristina D. Woodhouse, MD, Wei-Ting.

Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions Chelsea.

Efficacy and toxicity of rectal cancer reirradiation using IMRT for patients who have received prior pelvic radiation therapy Fady F. Youssef, MS, Parag.

Volume 105, Issue 3, Pages (March 1994)

Dosimetric analysis of varying cord planning organ at risk volume in spine stereotactic body radiation therapy Dawn Owen, MD, PhD, Charles S. Mayo, PhD,

Risk of carotid blowout after reirradiation with particle therapy

Continuing Risk of Ipsilateral Breast Relapse After Breast-Conserving Therapy at Long- Term Follow-up Bas Kreike, M.D., Augustinus A.M. Hart, M.Sc., Tony.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial Susanne M.

Higher-Than-Conventional Radiation Doses in Localized Prostate Cancer Treatment: A Meta-analysis of Randomized, Controlled Trials Gustavo Arruda Viani,

Effect of variations in atelectasis on tumor displacement during radiation therapy for locally advanced lung cancer Nathan Tennyson, MD, Elisabeth Weiss,

Volume 127, Issue 6, Pages (June 2005)

A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy William.

Volume 58, Issue 4, Pages (October 2010)

Tijana Skrepnik, MD, Silvija Gottesman, MD, Baldassarre Stea, MD, PhD

Radiation Therapy for Invasive Breast Cancer Increases the Risk of Second Primary Lung Cancer: A Nationwide Population-Based Cohort Analysis Yi-Jhih.

Cryptic Nocardia nova brain abscess postradiation treatment and neurosurgery in a patient with small cell lung cancer: A case report and review of the.

Claude C. Schulman, Jacques Irani, Juan Morote, Jack A

Impact of magnetic resonance imaging on computed tomography-based treatment planning and acute toxicity for prostate cancer patients treated with intensity.

Volume 72, Issue 5, Pages (November 2017)

Jennifer C. Ho, MD, Quynh-Nhu Nguyen, MD, Heng Li, PhD, Pamela K

Volume 64, Issue 6, Pages (December 2013)

The Role of Radiation Therapy in Malignant Thymoma: A Surveillance, Epidemiology, and End Results Database Analysis Annemarie T. Fernandes, BA, Eric.

Safety of differential radiation dosing in lymph node positive necks treated with IMRT Stephen Sozio, MBS, Zorimar Rivera-Núñez, PhD, Omar Mahmoud, MD,

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Risk Factors for the Development of Bone Metastases in Prostate Cancer

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base Amy C. Moreno,

Volume 15, Issue 4, Pages (April 2014)

Volume 55, Issue 6, Pages (June 2009)

Factors predicting patterns of recurrence after resection of N1 non-small cell lung carcinoma Timothy E Sawyer, MD, James A Bonner, MD, Perry M Gould,

A Combined Prognostic Serum Interleukin-8 and Interleukin-6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening.

Stereotactic body radiation therapy and 3-dimensional conformal radiotherapy for stage I non-small cell lung cancer: A pooled analysis of biological equivalent.

Patterns of regional failure in stage III non-small cell lung cancer treated with neoadjuvant chemoradiation therapy and resection Shalini Garg, MD,

Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic.

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Competing risks need to be considered in survival analysis models for cardiovascular outcomes Marianne Huebner, PhD, Martin Wolkewitz, Dr Sc Hum, Maurice.

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

Evaluating the prevalence and predictive factors of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy: Results.

Defining Optimal Comorbidity Measures for Patients With Early-Stage Non-small cell lung cancer Treated With Stereotactic Body Radiation Therapy Todd.

Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma Fauzia Shaikh, MD, Marjorie G. Zauderer,

Concurrent chemotherapy and intensity modulated radiation therapy in the treatment of anal cancer: A retrospective review from a large academic center

Does Granulocyte Colony–Stimulating Factor Affect Survival in Patients with Advanced Non-small Cell Lung Cancer? Goulnar Kasymjanova, MD, Harvey Kreisman,

Association between prior appendectomy and/or tonsillectomy in women and subsequent pregnancy rate: a cohort study Li Wei, Ph.D., Thomas MacDonald, M.D.,

Volume 155, Issue 1, Pages (January 2019)

Volume 9, Issue 8, Pages S14-S17 (August 2012)

Axel Heidenreich European Urology Supplements

Is the B12/CRP Index More Accurate Than You at Predicting Life Expectancy in Advanced Cancer Patients? Filipa Tavares, MD Journal of Pain and Symptom.

Should Patient-Rated Performance Status Affect Treatment Decisions in Advanced Lung Cancer? Esther Dajczman, RN, MScA, Goulnar Kasymjanova, MD, PhD,

Validation of the Modified Glasgow Prognostic Score in Advanced Cancer Patients Receiving Palliative Care Naitielle de Paula Pantano, RN, Bianca Sakamoto.

Definition of medical event is to be based on the total source strength for evaluation of permanent prostate brachytherapy: A report from the American.

Volume 53, Issue 6, Pages (June 2008)

It’s All in the “Swerve of the Curve”

Pulmonary Resection for Metastases from Colorectal Cancer

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

Guru Sonpavde, MD, Teresa G. Hayes, MD Mayo Clinic Proceedings

Axel Heidenreich European Urology Supplements

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Presentation transcript:

Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and high-risk prostate cancer Rafael Gadia, MD, Elton Trigo Teixeira Leite, MD, Ana Luiza Bierrenbach, PhD, Fabio Ynoe de Moraes, MD, Daniel E. Spratt, MD, Fernando Freire Arruda, MD, Carlos Eduardo Cintra Vita Abreu, MD, Joao Luis Fernandes da Silva, MD, Heloisa de Andrade Carvalho, PhD, Bernardo Garicochea, PhD Advances in Radiation Oncology Volume 1, Issue 4, Pages 300-309 (October 2016) DOI: 10.1016/j.adro.2016.10.006 Copyright © 2016 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions

Figure 1 Kaplan-Meier curves for biochemical failure by relevant risk factors: Nadir prostate-specific antigen levels (A) and risk classification (B). Advances in Radiation Oncology 2016 1, 300-309DOI: (10.1016/j.adro.2016.10.006) Copyright © 2016 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions

Figure 2 Kaplan-Meier curves for distant metastases by relevant risk factors: prostate-specific antigen nadir levels (A), risk classification (B), perineural invasion (C), and biochemical failure (D). Advances in Radiation Oncology 2016 1, 300-309DOI: (10.1016/j.adro.2016.10.006) Copyright © 2016 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions

Figure 3 Kaplan-Meier curves for deaths due to all causes by relevant risk factors: age (A), metastases (B), risk classification (C), and biochemical failure (D). Advances in Radiation Oncology 2016 1, 300-309DOI: (10.1016/j.adro.2016.10.006) Copyright © 2016 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions

Figure 4 Kaplan-Meier curves for deaths due to prostate cancer by relevant risk factors: age (A), metastases (B), risk classification (C), and biochemical failure (D). Advances in Radiation Oncology 2016 1, 300-309DOI: (10.1016/j.adro.2016.10.006) Copyright © 2016 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions